Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 259,720 shares, a growth of 88.8% from the June 30th total of 137,594 shares. Based on an average trading volume of 75,877 shares, the days-to-cover ratio is currently 3.4 days. Approximately 0.3% of the company’s shares are short sold.

Indaptus Therapeutics Trading Down 10.4%

INDP traded down $0.15 on Friday, hitting $1.29. The company had a trading volume of 92,506 shares, compared to its average volume of 473,491. The company’s fifty day moving average price is $2.70 and its 200 day moving average price is $2.35. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $8.69. The firm has a market cap of $146.08 million, a P/E ratio of -0.08 and a beta of 1.11.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Analyst Upgrades and Downgrades

INDP has been the topic of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.